Key result
Evinacumab reduces LDL-C by ~50% in homozygous familial hypercholesterolemia independent of LDLR function.
Why the study?
Most conventional lipid-lowering therapies for HoFH rely on LDLR-dependent mechanisms, limiting their effectiveness in patients with little to no LDLR activity, necessitating evaluation of LDLR-independent treatments like evinacumab.
Does evinacumab reduce LDL-C in individuals with homozygous familial hypercholesterolemia?
Does evinacumab reduce LDL-C in individuals with homozygous familial hypercholesterolemia?
Evinacumab provides an effective, LDLR-independent treatment option that reduces LDL-C by 40-50% in patients with homozygous familial hypercholesterolemia.
Supports evinacumab as adjunct in HoFH; extends synthesized evidence but leaves optimal sequencing open.
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder that results in severely elevated low-density lipoprotein cholesterol (LDL-C) due to dysfunctional activity of the low-density lipoprotein receptor (LDLR) and impaired clearance of LDL-C. Individuals with HoFH require intensive lipid-lowering therapies (LLTs), ideally starting in early childhood, to aggressively lower LDL-C levels and mitigate risk of early-onset atherosclerotic cardiovascular disease caused by lifetime exposure to high LDL-C levels. However, most conventional LLTs lower LDL-C through an LDLR-dependent mechanism, limiting their effectiveness in individuals with HoFH, who have little to no LDLR activity. Evinacumab is a fully human monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3), and has an LDLR-independent mechanism of action. By inhibiting ANGPTL3, evinacumab increases the activity of lipoprotein lipase and endothelial lipase, consequently increasing the clearance of LDL precursors and lowering LDL-C levels. Following its initial US Food and Drug Administration approval in 2021, evinacumab has been approved to treat individuals with HoFH from 1 year of age in the US and as young as 6 months of age in multiple other countries. Here, we describe the role of evinacumab in the HoFH treatment landscape, summarize the available clinical evidence for evinacumab, and provide practical guidance on its use from the clinician's perspective.
No takes yet. Share an insight, caveat, or question.
Bajaj et al. (2026) conducted a review in Homozygous familial hypercholesterolemia (HoFH). Evinacumab was evaluated on LDL-C reduction. Evinacumab, an ANGPTL3 inhibitor, reduces LDL-C by approximately 50% in patients with homozygous familial hypercholesterolemia, independent of LDLR activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: